Bulletin
Investor Alert

New York Markets Open in:

Cabaletta Bio Inc.

NAS: CABA

GO
/marketstate/country/us

Before the Bell

 --Quotes are delayed by 20 min

Sep 21, 2023, 8:19 a.m.

/zigman2/quotes/214676209/composite

$

15.92

Change

-0.11 -0.69%

Volume

Volume 204

Quotes are delayed by 20 min

/zigman2/quotes/214676209/composite

Previous close

$ 16.03

$ 16.03

Change

-1.33 -7.66%

Day low

Day high

$16.00

$17.35

Open

52 week low

52 week high

$0.59

$19.34

Open

Company Description

Cabaletta Bio, Inc. operates as a clinical-stage biotechnology company, which engages in the discovery and development of engineered T cell therapies for B cell-mediated autoimmune diseases. Its proprietary technology utilizes chimeric autoantibody receptor to selectively bind and eliminate B cells ...

Cabaletta Bio, Inc. operates as a clinical-stage biotechnology company, which engages in the discovery and development of engineered T cell therapies for B cell-mediated autoimmune diseases. Its proprietary technology utilizes chimeric autoantibody receptor to selectively bind and eliminate B cells that produce disease-causing autoantibodies. The company was founded by Michael C. Milone, Steven Nichtberger, and Aimee Payne in April 2017 and is headquartered in Philadelphia, PA.

Valuation

Price to Book Ratio

2.61

Enterprise Value to EBITDA

-12.70

Total Debt to Enterprise Value

0.03

Efficiency

Income Per Employee

-882,917.00

Liquidity

Current Ratio

11.47

Quick Ratio

11.47

Cash Ratio

11.23

Profitability

Return on Assets

-43.55

Return on Equity

-47.62

Return on Total Capital

-47.57

Return on Invested Capital

-47.00

Capital Structure

Total Debt to Total Equity

4.92

Total Debt to Total Capital

4.69

Total Debt to Total Assets

4.39

Long-Term Debt to Equity

2.83

Long-Term Debt to Total Capital

2.70

Officers and Executives

Name Age Officer Since Title
Dr. Steven Nichtberger 60 2017 Chairman, President & Chief Executive Officer
Mr. Anup Marda 41 2019 CFO & Principal Accounting Officer
Dr. Gwendolyn Binder-Scholl 45 2019 Executive Vice President-Science & Technology
Dr. David J. Chang 56 2019 Chief Medical Officer
Dr. Samik Basu - 2019 VP-Preclinical Research & Translational Medicine

Insider Actions

– Purchase – Sale 1 – Number of Transactions
Date Name Shares Transaction Value
08/21/2023 Gwendolyn Binder-Scholl
See Remarks
300   Disposition at $13.82 per share. 4,146
08/21/2023 Gwendolyn Binder-Scholl
See Remarks
10,700   Disposition at $13.41 per share. 143,487
08/21/2023 Gwendolyn Binder-Scholl
See Remarks
11,000   Derivative/Non-derivative trans. at $1.01 per share. 11,110
07/19/2023 Gwendolyn Binder-Scholl
See Remarks
2,815   Disposition at $14.26 per share. 40,141
07/19/2023 Gwendolyn Binder-Scholl
See Remarks
8,185   Disposition at $13.67 per share. 111,888
07/19/2023 Gwendolyn Binder-Scholl
See Remarks
11,000   Derivative/Non-derivative trans. at $1.01 per share. 11,110
06/20/2023 Gwendolyn Binder-Scholl
See Remarks
11,000   Disposition at $12.99 per share. 142,890
06/20/2023 Gwendolyn Binder-Scholl
See Remarks
11,000   Derivative/Non-derivative trans. at $1.01 per share. 11,110
05/19/2023 Gwendolyn Binder-Scholl
See Remarks
22,000   Disposition at $11.81 per share. 259,820
05/19/2023 Gwendolyn Binder-Scholl
See Remarks
22,000   Derivative/Non-derivative trans. at $1.01 per share. 22,220
10/19/2022 Steven Nichtberger
President & CEO; Director
8,127   Acquisition at $1.25 per share. 10,158
10/18/2022 Steven Nichtberger
President & CEO; Director
141,873   Acquisition at $0.99 per share. 140,454
10/18/2022 Mark Simon
Director
7,000   Acquisition at $0.98 per share. 6,860
10/18/2022 Mark Simon
Director
118,000   Acquisition at $0.98 per share. 115,640
10/18/2022 Anup Marda
Chief Financial Officer
50,000   Acquisition at $0.99 per share. 49,500
10/18/2022 Gwendolyn Binder-Scholl
See Remarks
20,000   Acquisition at $0.99 per share. 19,800
10/18/2022 Catherine Bollard
Director
1,000   Acquisition at $0.99 per share. 990
01/31/2022 Steven Nichtberger
President & CEO; Director
50,000   Derivative/Non-derivative trans. at $1.01 per share. 50,500
11/01/2021 5AM Venture Management LLC
36,544   Disposition at $13 per share. 475,072
11/01/2021 5AM Venture Management LLC
258,456   Disposition at $13 per share. 3,359,928
09/07/2021 5AM Venture Management LLC
625,000   Disposition at $9.7 per share. 6,062,500
01/12/2021 5AM Venture Management LLC
10,530   Disposition at $13 per share. 136,890
01/12/2021 5AM Venture Management LLC
74,470   Disposition at $13 per share. 968,110
/news/latest/company/us/caba

MarketWatch News on CABA

  1. Cabaletta Bio stock price target raised to $18 from $14 at Evercore ISI

    1:49 p.m. Feb. 16, 2023

    - Tomi Kilgore

  2. Cabaletta Bio stock price target cut to $10 from $20 at Mizuho

    6:57 a.m. May 25, 2022

    - Tomi Kilgore

  3. Cabaletta Bio initiated at buy with $21 price target at Chardan Research

    9:20 a.m. Jan. 8, 2021

    - Tonya Garcia

  4. Cabaletta Bio started at outperform with $25 stock price target at Evercore ISI

    8:40 a.m. Nov. 19, 2019

    - Tomi Kilgore

  5. Cabaletta Bio shares slide 17.6% in trading debut

    12:28 p.m. Oct. 25, 2019

    - Ciara Linnane

/news/nonmarketwatch/company/us/caba

Other News on CABA

  1. 10-Q: CABALETTA BIO, INC.

    7:40 a.m. May 11, 2023

    - Edgar Online - (EDG = 10Q, 10K)

  2. 10-Q: CABALETTA BIO, INC.

    8:44 a.m. Nov. 10, 2022

    - Edgar Online - (EDG = 10Q, 10K)

  3. 5 Stocks Insiders Are Buying in October

    4:56 p.m. Oct. 20, 2022

    - GuruFocus.com

  4. What Makes Cabaletta Bio, Inc. (CABA) a New Buy Stock

    12:00 p.m. June 9, 2022

    - Zacks.com

At a Glance

Cabaletta Bio, Inc.

2929 Arch Street

Suite 600

Philadelphia, Pennsylvania 19104

Phone

1 2677593100

Industry

Biotechnology

Sector

Health Care/Life Sciences

Fiscal Year-end

12/2023

Revenue

N/A

Net Income

$-52.98M

Employees

60.00

/news/pressrelease/company/us/caba

Press Releases on CABA

  1. Cabaletta Bio Announces $35 Million Offering

    8:01 a.m. Dec. 8, 2022

    - GlobeNewswire

Link to MarketWatch's Slice.